ZEP mainly engages in the import and export of pharmaceutical intermediates and APIs, with independent R&D of new crystalline APIs of non-infringement synthetic routes and pharmaceutical intermediates as its core.

ZEP has continuously increased its investment in independent R&D. In 2015, we established a professional R&D team for new crystalline APIs on non-infringement synthetic routes in the patent period. We constantly develop non-infringing processes by studying impurities, stability, method of analysis and Process Validation at the kilogram Level, along with exclusive licensing of patents or sub-contract production with factories having supported the production of first generics. All these efforts aim at supporting our customers in their challenging of primary drug and production of first generics.

Our R&D team has applied for a number of international patents, some of which have been authorized and converted into commercial products, which has successfully contributed to the ANDA application of many customers.

The business team keep on improving their service, and provides added value to customers with highly cohesive teamwork and highly specialized services.

We have independent QA department to perform pre-audit, supporting regulations and registration. It offers valuable references for customers to select high-quality suppliers at early stage, provide professional corrections to suppliers about their quality and file management system. Meanwhile, in order to enhance the professional capabilities, we provide regular training about regulations and quality systems for our employees.

With constant efforts in all aspects in recent years, our company has gained rapid development which shows in rises in sales, nearly 500 million yuan in 2021. Now we has formed a market layout mainly in Korea, Japan, India and Europe, supplemented by Egypt, Pakistan and South America, and continues to penetrate into other markets.